PRICE

The global Platelet Aggregation Devices Market is projected to grow at a CAGR of approximately 19% during the forecast period (2018-2023). Platelet aggregation is a process where human platelet cells are involved in hemostasis, bleeding to repair, and vessel constriction. Additionally, platelet aggregation plays a crucial role in the inflammation and other pathological situations. Platelet aggregation test involves venipuncture in an anti-coagulant medium. This is followed by centrifugation to produce plasma which is rich in platelets, where aggregometers are used to study the platelet aggregation.

Technological Advancements in Platelet Aggregometry

Traditional aggregometers work on the principle of light transmission. The traditional aggregometers perform light transmission aggregometry (LTA) which was once considered as the gold standard for platelet function testing, and is still used for the identification and diagnosis of platelet function defects. LTA involves using a sample of platelet rich plasma (PRP), which is stirred within a cuvette and then subjected to a light source, for detecting light transmission. Traditional LTA remains the most useful technique for diagnosing a wide variety of platelet defects. The main disadvantage of LTA is the use of PRP instead of the whole blood under relatively low shear conditions, and, in the absence of red and white cells, it does not accurately simulate primary hemostasis. Additionally, LTA requires large sample volume, is time-consuming, and there are many pre-analytical and analytical variables that affect the LTA results. These shortcoming in traditional aggregometry spurred the development and advancement of aggregometry techniques which is widely being adopted in the current market. The platelet function analyzers (PFA) are the result of such developments. The platelet function tests performed through a PFA are automated, rapid and mimics several characteristics of physiologic platelet function, because it is a high shear system. Additionally, PFA makes use of whole blood samples instead of PRP. Consequently, the advancements in aggregometry are improving the adoption rate of these devices and in turn helping in the growth of the global platelet aggregation devices market.

Procedural Limitations in Pediatrics

One of the major limitations of light transmission aggregometry (LTA) is that the method is time‐ and labor-intensive and requires a large volume of blood. The latter presents significant challenges when platelet function needs to be assessed in pediatric patients, in whom the volume of blood sample is usually very limited. To overcome these limitations various high throughput methods are being developed to measure platelet aggregation in PRP using lyophilized reagents which offers simultaneous assessment of several platelet activation pathways in a smaller volume of PRP. These throughput methods might be useful in the future as a screening tool that can be available in non‐specialized laboratories once this test is validated further and becomes commercially available. But in the current market, the limitations of LTA especially in pediatrics is causing significant hindrance to market growth. Additionally, the issue of low blood samples in pediatrics is further compounded by the short shelf life of PRP. PRP sample once prepared needs to be kept in temperature controlled environment and it cannot be stored for more than a couple of hours even in most suitable conditions, after which aggregation is auto induced due to platelet activation, rendering the PRP useless for platelet function testing.

North America Accounted for Largest Market Share

The North America region accounted for the largest market share in Global Platelet Aggregation Devices Market, in 2017. North America is also expected to show highest growth over the forecast period. The largest market share of North America can be attributed to the strong presence of device manufacturers in the region, growing number of surgical procedures, and rising awareness among healthcare professionals regarding the benefits offered by platelet aggregation testing in disease diagnosis. Additionally factors like large number of patients undergoing cardiovascular surgeries, and increasing prevalence of orthopedic, urological, and bleeding disorders is expected to sustain the market leader status of North America supported by high growth rate.

Key Developments in Platelet Aggregation Devices Market

• Feb 2018: Abcam, a global innovator in life science reagents and tools, and Molecular Devices, LLC, a leading provider of high-performance bioanalytical measurement solutions, announced a strategic collaboration to develop a wide range of fast and reproducible screening tools for researchers.

• Current and future Global Platelet Aggregation Devices market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players.
• 3-month analyst support along with the Market Estimate sheet in (Excel).

Customization of the Report

• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.